0.67 USD
▲+0.04+5.50%
盘后 0.66 -2.02%
2026-09-15
市值
$164.79M
市盈率
—
EPS
-0.75
股息率
—
52 周区间
0.16 – 2.54
成交量
4.52M
Beta
0.75
目标价
5.03
52W 低 0.1652W 高 2.54
价格走势
公司简介
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, ...